NV1020 is an oncolytic herpes virus initially developed by Medigene Inc. and licensed for development by Catherex Inc. in 2010 [REF].
A Phase I/II study completed in 2008 evaluating NV1020 for treatment of metastatic colorectal cancer in the liver [REF].